Valuation: Valneva SE Pref.

Market Cap 423M 483M 391M 365M 687M 45.71B 703M 4.7B 1.82B 22.55B 1.82B 1.78B 78.28B P/E 2026 *
-6.08x
P/E 2027 * 5.87x
Enterprise Value 551M 630M 509M 475M 895M 59.53B 915M 6.12B 2.36B 29.37B 2.36B 2.31B 102B EV / Sales 2026 *
3.63x
EV / Sales 2027 * 1.64x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Valneva SE Pref.

Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 483M
+0.94%+7.83%-4.50%+3.17% 46.2B
+2.80%+12.12%+405.33%+609.04% 38.71B
+0.05%+13.76%+21.14%-13.78% 31.9B
+2.73%+5.53%+18.49%+60.60% 31.12B
+8.02%+5.23%+17.67%+35.36% 23.77B
+0.34%+14.22% - - 16.2B
-0.06%+15.30%+67.39%+123.62% 15.05B
-1.13%+7.40%+12.81%+20.67% 13.74B
-0.46%+6.29%+104.15%+96.21% 13.42B
Average +1.26%+10.60%+80.31%+116.86% 25.57B
Weighted average by Cap. +1.66%+10.07%+92.28%+137.65%

Financials

2026 *2027 *
Net sales 152M 173M 140M 131M 246M 16.39B 252M 1.69B 651M 8.09B 651M 637M 28.08B 294M 336M 271M 253M 477M 31.75B 488M 3.27B 1.26B 15.66B 1.26B 1.23B 54.38B
Net income -66.01M -75.39M -60.94M -56.91M -107M -7.13B -110M -733M -283M -3.52B -283M -277M -12.21B 70.5M 80.52M 65.08M 60.78M 114M 7.61B 117M 783M 302M 3.76B 302M 296M 13.04B
Net Debt 128M 146M 118M 110M 208M 13.82B 212M 1.42B 549M 6.82B 549M 537M 23.68B 60.02M 68.54M 55.41M 51.74M 97.4M 6.48B 99.62M 667M 257M 3.2B 257M 252M 11.1B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.232EUR
Average target price
5.233EUR
Spread / Average Target
+134.47%

Quarterly revenue - Rate of surprise